These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33458944)

  • 1. Associations between peak oxygen uptake, lung function, and bronchiectasis in children with cystic fibrosis in the era of CFTR modulators.
    Du Berry C; Westrupp N; Shanthikumar S; Welsh L
    Pediatr Pulmonol; 2021 Jun; 56(6):1490-1495. PubMed ID: 33458944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiopulmonary exercise testing in children with cystic fibrosis: one centre's experience.
    Weir E; Burns PD; Devenny A; Young D; Paton JY
    Arch Dis Child; 2017 May; 102(5):440-444. PubMed ID: 27919886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CFTR Genotype and Maximal Exercise Capacity in Cystic Fibrosis: A Cross-sectional Study.
    Radtke T; Hebestreit H; Gallati S; Schneiderman JE; Braun J; Stevens D; Hulzebos EH; Takken T; Boas SR; Urquhart DS; Lands LC; Tejero S; Sovtic A; Dwyer T; Petrovic M; Harris RA; Karila C; Savi D; Usemann J; Mei-Zahav M; Hatziagorou E; Ratjen F; Kriemler S;
    Ann Am Thorac Soc; 2018 Feb; 15(2):209-216. PubMed ID: 29140739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiopulmonary exercise testing with supramaximal verification produces a safe and valid assessment of V̇o
    Causer AJ; Shute JK; Cummings MH; Shepherd AI; Bright V; Connett G; Allenby MI; Carroll MP; Daniels T; Saynor ZL
    J Appl Physiol (1985); 2018 Oct; 125(4):1277-1283. PubMed ID: 30346240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exercise capacity in patients with cystic fibrosis vs. non-cystic fibrosis bronchiectasis.
    Bar-Yoseph R; Ilivitzki A; Cooper DM; Gur M; Mainzer G; Hakim F; Livnat G; Schnapp Z; Shalloufeh G; Zucker-Toledano M; Subar Y; Bentur L
    PLoS One; 2019; 14(6):e0217491. PubMed ID: 31194748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Epididymis Protein 4: A Novel Serum Inflammatory Biomarker in Cystic Fibrosis.
    Nagy B; Nagy B; Fila L; Clarke LA; Gönczy F; Bede O; Nagy D; Újhelyi R; Szabó Á; Anghelyi A; Major M; Bene Z; Fejes Z; Antal-Szalmás P; Bhattoa HP; Balla G; Kappelmayer J; Amaral MD; Macek M; Balogh I
    Chest; 2016 Sep; 150(3):661-72. PubMed ID: 27105680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Fitter the Better? Cardiopulmonary Exercise Testing Can Predict Pulmonary Exacerbations in Cystic Fibrosis.
    Kampouras A; Hatziagorou E; Kalantzis T; Avramidou V; Kontouli K; Kirvassilis F; Tsanakas J
    Children (Basel); 2021 Jun; 8(6):. PubMed ID: 34205505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bronchiectases at early chest computed tomography in children with cystic fibrosis are associated with increased risk of subsequent pulmonary exacerbations and chronic pseudomonas infection.
    Bortoluzzi CF; Volpi S; D'Orazio C; Tiddens HA; Loeve M; Tridello G; Assael BM
    J Cyst Fibros; 2014 Sep; 13(5):564-71. PubMed ID: 24726420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of CFTR modulators on exercise capacity in adolescents with cystic fibrosis.
    Ahmed MI; Dayman N; Blyth N; Madge J; Gaillard E
    ERJ Open Res; 2024 Jan; 10(1):. PubMed ID: 38375430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of pancreatic status, CFTR mutations, Staphylococcus aureus and/or Pseudomonas aeruginosa infection/colonization on lung function in cystic fibrosis during a 2-year follow-up period.
    Pascoal MA; Marson FAL; Paschoal IA; Levy CE
    Wien Klin Wochenschr; 2020 Oct; 132(19-20):572-580. PubMed ID: 32356101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of peak oxygen uptake using the modified shuttle test in children and adolescents with cystic fibrosis.
    Vendrusculo FM; Heinzmann-Filho JP; Campos NE; Gheller MF; de Almeida IS; Donadio MVF
    Pediatr Pulmonol; 2019 Apr; 54(4):386-392. PubMed ID: 30614221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative sensitivity of early cystic fibrosis lung disease detection tools in school aged children.
    Bayfield KJ; Weinheimer O; Middleton A; Boyton C; Fitzpatrick R; Kennedy B; Blaxland A; Jayasuriya G; Caplain N; Wielpütz MO; Yu L; Galban CJ; Robinson TE; Bartholmai B; Gustafsson P; Fitzgerald D; Selvadurai H; Robinson PD
    J Cyst Fibros; 2024 Sep; 23(5):918-925. PubMed ID: 38969602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment.
    Edgeworth D; Keating D; Ellis M; Button B; Williams E; Clark D; Tierney A; Heritier S; Kotsimbos T; Wilson J
    Clin Sci (Lond); 2017 Aug; 131(15):2037-2045. PubMed ID: 28611235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
    Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
    Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection.
    Ziedalski TM; Kao PN; Henig NR; Jacobs SS; Ruoss SJ
    Chest; 2006 Oct; 130(4):995-1002. PubMed ID: 17035430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung clearance index (LCI) as a predictor of exercise limitation among CF patients.
    Avramidou V; Hatziagorou E; Kampouras A; Hebestreit H; Kourouki E; Kirvassilis F; Tsanakas J
    Pediatr Pulmonol; 2018 Jan; 53(1):81-87. PubMed ID: 28950435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
    Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis.
    Westhölter D; Beckert H; Straßburg S; Welsner M; Sutharsan S; Taube C; Reuter S
    J Cyst Fibros; 2021 Nov; 20(6):1072-1079. PubMed ID: 34030985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation.
    Burghard MM; Berkers GG; Ghijsen SS; Hollander-Kraaijeveld FF; de Winter-de Groot KK; van der Ent CK; Heijerman HH; Takken TT; Hulzebos HE
    Pediatr Pulmonol; 2020 Jun; 55(6):1400-1405. PubMed ID: 32233113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.